The House Committee on Oversight and Government Reform yesterday held a hearing on the rising price of a device used to inject the drug epinephrine to treat severe allergic reactions. While the EpiPen Auto-Injector has been on the market since 1988, the price for a two-pack of the devices has increased more than 500% over the past decade, according to the committee. Witnesses at the hearing included Heather Bresch, the CEO of Mylan Inc., which acquired the product in 2007; and Doug Throckmorton, deputy director of the Food and Drug Administration’s Center for Drug Evaluation and Research. According to Throckmorton, there are currently no FDA-approved generic epinephrine auto-injectors.